Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2–advanced breast cancer

被引:0
作者
Qi Zhao
Mingxia Jiang
Jiaxuan Liu
Mengqi Zhang
Maiyue He
Shihan Zhou
Jiani Wang
Hongnan Mo
Bo Lan
Peng Yuan
Pin Zhang
Fei Ma
Qiao Li
Binghe Xu
机构
[1] DepartmentofMedicalOncology,NationalCancerCenter/NationalClinicalResearchCenterforCancer/CancerHospital,ChineseAcademyofMedicalSciencesandPekingUnionMedicalCollege
关键词
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
摘要
Objective: CDK4/6 inhibitors(CDK4/6is) in combination with endocrine therapy have secured a central role in the treatment of hormone receptor(HR)-positive advanced breast cancer(ABC) and have transformed the therapeutic landscape. Cross-line CDK4/6i therapy in which another CDK4/6i is continued after progression on a prior CDK4/6i may still offer advantageous therapeutic effects. Cross-line CDK4/6i therapy is an area of active investigation in the ongoing pursuit to improve outcomes for patients with HR+/human epidermal growth factor receptor 2(HER2)± ABC.Methods: This retrospective study enrolled 82 patients with HR+/HER2± ABC who were treated with cross-line CDK4/6is(abemaciclib, palbociclib, ribociclib, and dalpiciclib) after progression with another CDK4/6i. The primary endpoint was progressionfree survival(PFS) according to version 1.1 of the Response Evaluation Criteria in Solid Tumors. Secondary endpoints included toxicity, objective response rate, disease control rate, and overall survival. Adverse events(AEs) were graded according to version 5.0 of the Common Terminology Criteria for Adverse Events, as promulgated by the U.S. Department of Health and Human Services.Results: Eighty-two HR+/HER2± ABC patients who received cross-line CDK4/6i therapy from January 2022 to February 2024 were enrolled. The median age of the patients was 60 years. The median PFS of all patients was 7.6 months(95% CI, 5.9-9.2). Cox regression analysis identified lung metastasis and a switch to endocrine therapy following prior CDK4/6i therapy as independent predictive factors for PFS. Notably, patients who previously received abemaciclib and switched to palbociclib upon disease progression had a median PFS of 10.7 months. The strategy of transitioning to chemotherapy after progression on a prior CDK4/6i, then to a subsequent CDK4/6i merits further investigation. Hematologic toxicity was the most common grade ≥ 3 AEs. No instances of fatal safety events were observed.Conclusions: Cross-line CDK4/6i therapy is associated with significant clinical benefits and manageable safety profiles in patients with HR+/HER2± ABC, which underscores cross-line CDK4/6i therapy potential as an effective treatment strategy.
引用
收藏
页码:934 / 950
页数:17
相关论文
共 29 条
[1]  
Current cancer burden in China: epidemiology; etiology; and prevention.[J].Maomao Cao;He Li;Dianqin Sun;Siyi He;Xinxin Yan;Fan Yang;Shaoli Zhang;Changfa Xia;Lin Lei;Ji Peng;Wanqing Chen;.Cancer Biology & Medicine.2022, 08
[2]  
Chinese Society of Clinical Oncology Breast Cancer(CSCO BC) guidelines in 2022: stratification and classification.[J].Jianbin Li;Zefei Jiang;.Cancer Biology & Medicine.2022, 06
[3]  
Breast cancer screening and early diagnosis in Chinese women.[J].Rui Ding;Yi Xiao;Miao Mo;Ying Zheng;Yi-Zhou Jiang;Zhi-Ming Shao;.Cancer Biology & Medicine.2022, 04
[4]   The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment [J].
Morrison, Laura ;
Loibl, Sibylle ;
Turner, Nicholas C. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (02) :89-105
[5]   Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers [J].
Navarro-Yepes, Juliana ;
Kettner, Nicole M. ;
Rao, Xiayu ;
Bishop, Cassandra Santaella ;
Bui, Tuyen N. ;
Wingate, Hannah F. ;
Singareeka Raghavendra, Akshara ;
Wang, Yan ;
Wang, Jing ;
Sahin, Aysegul A. ;
Meric-Bernstam, Funda ;
Hunt, Kelly K. ;
Damodaran, Senthil ;
Tripathy, Debu ;
Keyomarsi, Khandan .
CANCER RESEARCH, 2023, 83 (19) :3264-3283
[6]   Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer A Review [J].
O'Sullivan, Ciara Catherine ;
Clarke, Robert ;
Goetz, Matthew Philip ;
Robertson, John .
JAMA ONCOLOGY, 2023, 9 (09) :1273-1282
[7]   Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer [J].
Turner, Nicholas C. ;
Oliveira, Mafalda ;
Howell, Sacha J. ;
Dalenc, Florence ;
Cortes, Javier ;
Moreno, Henry L. Gomez ;
Hu, Xichun ;
Jhaveri, Komal ;
Krivorotko, Petr ;
Loibl, Sibylle ;
Morales Murillo, Serafin ;
Okera, Meena ;
Park, Yeon Hee ;
Sohn, Joohyuk ;
Toi, Masakazu ;
Tokunaga, Eriko ;
Yousef, Samih ;
Zhukova, Lyudmila ;
de Bruin, Elza C. ;
Grinsted, Lynda ;
Schiavon, Gaia ;
Foxley, Andrew ;
Rugo, Hope S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (22) :2058-2070
[8]   Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? [J].
Corti, Chiara ;
De Angelis, Carmine ;
Bianchini, Giampaolo ;
Malorni, Luca ;
Giuliano, Mario ;
Hamilton, Erika ;
Jeselsohn, Rinath ;
Jhaveri, Komal ;
Curigliano, Giuseppe ;
Criscitiello, Carmen .
CANCER TREATMENT REVIEWS, 2023, 117
[9]   Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer [J].
Huppert, Laura A. ;
Gumusay, Ozge ;
Idossa, Dame ;
Rugo, Hope S. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2023, 73 (05) :480-515
[10]   Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer-A Review of the Literature [J].
Stanciu, Ioana-Miruna ;
Parosanu, Andreea Ioana ;
Orlov-Slavu, Cristina ;
Iaciu, Ion Cristian ;
Popa, Ana Maria ;
Olaru, Cristina Mihaela ;
Pirlog, Cristina Florina ;
Vrabie, Radu Constantin ;
Nitipir, Cornelia .
DIAGNOSTICS, 2023, 13 (05)